Featured Research

from universities, journals, and other organizations

HIV drug shows efficacy in treating mouse models of HER2+ breast cancer, study suggests

Date:
October 5, 2012
Source:
Journal of the National Cancer Institute
Summary:
The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a new study.

The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of the National Cancer Institute.

Breast cancer is one of the most common causes of cancer deaths in the U.S. with approximately 39,520 women succumbing to the disease in 2011. HER2-postive breast cancer is known to be more aggressive and less responsive to treatments compared to other types of breast cancer. Nelfinavir has been shown to inhibit the growth of some types of cancers and has been used in clinical trials as either a chemotherapeutic agent or a radiosensitizer for cancer therapy. However, its effect on HER2-positive breast cancer is unknown.

In order to determine the effects of Nelfinavir on HER2-positive breast cancer, Joong Sup Shim, Ph.D., of the Department of Pharmacology and Molecular Sciences at Johns Hopkins School of Medicine and colleagues screened the Johns Hopkins Drug Library and identified a number of inhibitors of breast cancer cells, a subset of which was then used to pharmacologically profile seven genotypically individual breast cancer cell lines. After identifying Nelfinavir as a selective inhibitor of HER2-positive cells, the researchers determined the antitumor activity of the inhibitor in mouse models of human breast cancer.

The researchers found that Nelfinavir inhibited the growth of HER2-positive tumors in mice. They also found that the concentrations of Nelfinavir needed to inhibit HER2-positive cancer cells in vitro are consistent with dosage regimens used for HIV patients. "With a relatively low toxicity profile and much available information on its drug-drug interactions and on pharmacokinetics, Nelfinavir is ready for clinical testing in HER2 breast cancer patients," the authors write, adding that this discovery has, "important implications in the development of Nelfinavir and its analogs as new anticancer agents."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Joong Sup Shim, Rajini Rao, Kristin Beebe, Len Neckers, Inkyu Han, Rita Nahta, and Jun O. Liu. Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir. J Natl Cancer Inst, October 5, 2012 DOI: 10.1093/jnci/djs396

Cite This Page:

Journal of the National Cancer Institute. "HIV drug shows efficacy in treating mouse models of HER2+ breast cancer, study suggests." ScienceDaily. ScienceDaily, 5 October 2012. <www.sciencedaily.com/releases/2012/10/121005162819.htm>.
Journal of the National Cancer Institute. (2012, October 5). HIV drug shows efficacy in treating mouse models of HER2+ breast cancer, study suggests. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2012/10/121005162819.htm
Journal of the National Cancer Institute. "HIV drug shows efficacy in treating mouse models of HER2+ breast cancer, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/10/121005162819.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


HIV and Breast Cancer May Share a Common Enemy: Nelfinavir

Oct. 11, 2012 After screening more than 2,300 drugs for their ability to halt the growth of breast cancer cells, researchers have discovered that the anti-HIV drug nelfinavir slows the progress of HER2-positive ... read more

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins